Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more
Beam Therapeutics Inc (BEAM) - Net Assets
Latest net assets as of December 2025: $1.24 Billion USD
Based on the latest financial reports, Beam Therapeutics Inc (BEAM) has net assets worth $1.24 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.48 Billion) and total liabilities ($242.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.24 Billion |
| % of Total Assets | 83.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | 49.79% |
| 10-Year Change | N/A |
| Growth Volatility | 91.36 |
Beam Therapeutics Inc - Net Assets Trend (2017–2025)
This chart illustrates how Beam Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beam Therapeutics Inc (2017–2025)
The table below shows the annual net assets of Beam Therapeutics Inc from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.24 Billion | +68.82% |
| 2024-12-31 | $733.54 Million | -25.25% |
| 2023-12-31 | $981.33 Million | +33.79% |
| 2022-12-31 | $733.47 Million | -11.28% |
| 2021-12-31 | $826.74 Million | +236.67% |
| 2020-12-31 | $245.56 Million | +143.26% |
| 2019-12-31 | $100.94 Million | -24.68% |
| 2018-12-31 | $134.03 Million | +3304.11% |
| 2017-12-31 | $-4.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beam Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 163175800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.02 Million | 0.08% |
| Other Comprehensive Income | $1.11 Million | 0.09% |
| Other Components | $2.88 Billion | 232.36% |
| Total Equity | $1.24 Billion | 100.00% |
Beam Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Beam Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Universal Microwave Technology
TWO:3491
|
$2.27 Billion |
|
Shenzhen Senior Technology Material Co Ltd
SHE:300568
|
$2.28 Billion |
|
First Merchants Corporation
NASDAQ:FRME
|
$2.28 Billion |
|
China National Building Material Company Limited
F:D1Y
|
$2.28 Billion |
|
Zhongyuan Bank Co., Ltd.
PINK:ZNNGY
|
$2.27 Billion |
|
Seadrill Limited
NYSE:SDRL
|
$2.27 Billion |
|
Hanesbrands Inc
NYSE:HBI
|
$2.27 Billion |
|
DKSH Holding AG
SW:DKSH
|
$2.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beam Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 733,545,000 to 1,238,358,000, a change of 504,813,000 (68.8%).
- Net loss of 79,992,000 reduced equity.
- New share issuances of 470,513,000 increased equity.
- Other comprehensive income increased equity by 432,000.
- Other factors increased equity by 113,860,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-79.99 Million | -6.46% |
| Share Issuances | $470.51 Million | +37.99% |
| Other Comprehensive Income | $432.00K | +0.03% |
| Other Changes | $113.86 Million | +9.19% |
| Total Change | $- | 68.82% |
Book Value vs Market Value Analysis
This analysis compares Beam Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.32 | $25.83 | x |
| 2018-12-31 | $3.81 | $25.83 | x |
| 2019-12-31 | $1.97 | $25.83 | x |
| 2020-12-31 | $5.25 | $25.83 | x |
| 2021-12-31 | $12.87 | $25.83 | x |
| 2022-12-31 | $10.48 | $25.83 | x |
| 2023-12-31 | $12.72 | $25.83 | x |
| 2024-12-31 | $8.91 | $25.83 | x |
| 2025-12-31 | $12.52 | $25.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beam Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -57.24%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.20x
- Recent ROE (-6.46%) is above the historical average (-44.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.31 Million |
| 2018 | -85.99% | 0.00% | 0.00x | 1.25x | $-128.66 Million |
| 2019 | -77.59% | -435144.44% | 0.00x | 1.55x | $-88.42 Million |
| 2020 | -79.24% | -810800.00% | 0.00x | 1.84x | $-219.15 Million |
| 2021 | -44.83% | -714.91% | 0.04x | 1.78x | $-453.31 Million |
| 2022 | -39.41% | -474.54% | 0.05x | 1.83x | $-362.44 Million |
| 2023 | -13.50% | -35.09% | 0.26x | 1.49x | $-230.66 Million |
| 2024 | -51.36% | -593.13% | 0.06x | 1.50x | $-450.10 Million |
| 2025 | -6.46% | -57.24% | 0.09x | 1.20x | $-203.83 Million |
Industry Comparison
This section compares Beam Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beam Therapeutics Inc (BEAM) | $1.24 Billion | 0.00% | 0.20x | $2.27 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |